Shares of Alcon Inc. (ALC) surged 5.06% in intraday trading on Tuesday following the release of the company's third-quarter 2025 financial results. The eye care giant reported earnings that exceeded analyst expectations, despite a slight miss on revenue estimates.

Alcon posted quarterly earnings of $0.79 per share, surpassing the analyst consensus estimate of $0.76 by 3.95%. While this represents a slight decrease from the $0.81 per share reported in the same period last year, investors appeared to focus on the positive aspects of the report. The company's quarterly sales reached $2.589 billion, just shy of the $2.603 billion analyst estimate, but still marking a 6.41% increase from the previous year.

The stock's impressive rally can be attributed to several factors highlighted in the earnings report. Notably, Alcon experienced strong growth in equipment sales, with a 13% increase on both a reported and constant currency basis. This growth was led by recent equipment launches, including the Unity VCS system. Additionally, the company reported solid performance in its ocular health segment, driven by products for dry eye and glaucoma, such as Systane, Tryptyr, and Rocklatan. Investors also seemed encouraged by the positive momentum of new products like PanOptix Pro in the implantables category. Despite facing some competitive pressures, Alcon maintained its full-year 2025 guidance, further boosting investor confidence in the company's outlook.